Curis Inc (CRIS)
NASDAQ:CRIS
Want to see CRIS full AI Analyst Report?
CRIS Stock Chart & Stats
$0.60
-$0.29(-7.77%)
At close: 4:00 PM EST
$0.60
-$0.29(-7.77%)
Day’s Range― - ―
52-Week Range$0.46 - $3.13
Previous CloseN/A
Volume44.55K
Average Volume (3M)68.01K
Market Cap
$22.10M
Enterprise Value-$6.20M
Total Cash (Recent Filing)$15.00M
Total Debt (Recent Filing)$1.34M
Price to Earnings (P/E)―
Beta3.01
Next Earnings
Jul 30, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding38,978,690
10 Day Avg. Volume74,344
30 Day Avg. Volume68,010
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)23.79
Price to Sales (P/S)13.76
P/FCF Ratio-4.78
Enterprise Value/Market Cap-0.28
Enterprise Value/Revenue-0.88
Enterprise Value/Gross Profit-0.88
Enterprise Value/Ebitda0.83
Forecast
1Y Price Target
$11.00Price Target Upside1733.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.82
Revenue Forecast (FY)$7.55M
Bulls Say, Bears Say
Bulls Say
Registrational Clinical ProgressAdvancement of a registrational PCNSL study with an ORR endpoint and anticipated combo data provides a clear regulatory path and near-term data catalysts. A registrational program that supports accelerated submissions materially reduces long-term binary development risk versus preclinical assets.
Regulatory And Collaborator EngagementDeep partnerships and active FDA/EMA dialogue strengthen trial designs, speed regulatory alignment, and leverage external capabilities. This de-risks development execution, improves trial quality and could accelerate approvals or pathway decisions over the next several months.
Low Leverage On The Balance SheetModest debt lowers mandatory interest and refinancing pressure, preserving financial flexibility while clinical programs advance. Low leverage helps avoid forced asset sales or heavy interest burden, sustaining runway options and strategic choices during the development cycle.
Bears Say
High Cash Burn And Negative FCFSustained negative operating and free cash flow means the business cannot self-fund development. Over the coming months this persistent burn necessitates external financing, increases dilution risk, and constrains strategic flexibility if clinical timelines slip.
Runway Depends On Contingent Warrant ProceedsReliance on milestone-contingent warrant exercises ties the balance sheet to trial enrollment execution. If dosing is delayed or contingent conditions unmet, the company faces accelerated funding needs, increasing the likelihood of dilutive financings or disrupted programs.
Nasdaq Listing And Liquidity RiskA delisting determination creates structural uncertainty for liquidity, institutional participation, and future capital access. Accelerated delisting risk could materially constrain fundraising options and investor base if the appeal fails within the next several months.
Curis News
CRIS FAQ
What was Curis Inc’s price range in the past 12 months?
Curis Inc lowest stock price was $0.46 and its highest was $3.13 in the past 12 months.
What is Curis Inc’s market cap?
Curis Inc’s market cap is $22.10M.
When is Curis Inc’s upcoming earnings report date?
Curis Inc’s upcoming earnings report date is Jul 30, 2026 which is in 60 days.
How were Curis Inc’s earnings last quarter?
Curis Inc released its earnings results on May 12, 2026. The company reported -$1.25 earnings per share for the quarter, missing the consensus estimate of -$0.327 by -$0.923.
Is Curis Inc overvalued?
According to Wall Street analysts Curis Inc’s price is currently Undervalued.
Does Curis Inc pay dividends?
Curis Inc does not currently pay dividends.
What is Curis Inc’s EPS estimate?
Curis Inc’s EPS estimate is -0.41.
How many shares outstanding does Curis Inc have?
Curis Inc has 38,978,690 shares outstanding.
What happened to Curis Inc’s price movement after its last earnings report?
Curis Inc reported an EPS of -$1.25 in its last earnings report, missing expectations of -$0.327. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Curis Inc?
Currently, no hedge funds are holding shares in CRIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
CRIS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical progress and clear near‑term milestones — notably advancement of a registrational PCNSL study with the potential for accelerated submissions, initiation and early milestones for a CLL proof‑of‑concept study, encouraging early collaborator data in gastroesophageal cancer, and collaborative/regulatory engagement. Offsetting these positives are a sizable increase in reported net loss (driven by warrant fair‑value changes), higher G&A tied to financing, a cash runway that depends in part on a milestone contingent warrant exercise, and expected enrollment variability in ultra‑orphan indications. On balance, the clinical and regulatory momentum and near‑term data/milestone visibility materially outweigh the financial and enrollment risks described.View all CRIS earnings summariesCRIS Stock 12 Month Forecast
Average Price Target
$11.00
▲(1733.33% Upside)
Technical Analysis
Ownership Overview
1.02% Insiders
1.20% Mutual Funds
36.28% Other Institutional Investors
60.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---